(Alliance News) - Shield Therapeutics PLC on Thursday said it has raised GBP2.6 million through an open offer.

In December, the Gateshead, England-based commercial-stage pharmaceutical firm said it plans to raise GBP18.6 million in total, including an aggregate GBP14.7 million from placing and subscription at a price of 6.00 pence, alongside raising a further GBP3.9 million via an open offer to shareholders of 64.3 million shares.

It noted the issue price represented an 11% discount to the share closing price on December 12, the last business day before the announcement. Shares in Shield Therapeutics traded down 3.6% at 6.80p each in London on Tuesday morning.

On Thursday, Shield Therapeutics said it had raised GP2.6 million through the open offer. In total, the company has offer 43.3 million shares at 6.00p, this represents 67% of the total number of open offer shares available to shareholders.

As part of the open offer, Non-Executive Director Christian Schweiger bought 1.5 million shares, worth GBP90,000.

In total, Shield Therapeutics has raised around GBP17.7 million by way of the placing, subscription and open offer.

Chief Executive Greg Madison said: "We are extremely pleased to have concluded the fundraise with a successful open offer raising approximately GBP2.6 million. The open offer along with the GBP15.1 million equity fundraise announced in December, will enable Shield to accelerate the revenue growth of Accrufer in the

US."

By Sophie Rose; Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.